Hematopoietic Stem Cell Transplant: A Viable Option for Older Patients With AML

Mark B. Juckett, MD
Published: Friday, Mar 27, 2020
Carbone Cancer CenterMark B. Juckett, MD
Mark B. Juckett, MD
Vice Chair, Clinical Affairs and Quality, Department of Medicine, University of Wisconsin, and Director, Bone Marrow

Transplant Program, University of

Wisconsin Carbone Cancer Center

Strategic Partnership
Acute myeloid leukemia (AML) is diagnosed at a median age of 68 years, well beyond an age in which intensive therapy and allogeneic hematopoietic stem cell transplantation (HSCT) is typically considered an option. This approach is not easily applied to patients 60 years and older because of limitations caused by comorbidities, performance status, and frailty. In addition, older patients (here defined as those 60 years and older) tend to have disease that is more aggressive, harbors high-risk cytogenetics or molecular lesions (ie, p53 mutations), and is less sensitive to cytotoxic chemotherapy.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication